Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies and vaccines for rare diseases and global health issues. The company's pipeline, including its Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform, shows significant potential for treating a range of inherited retinal diseases and COVID-19. The company's recent debt offering has also provided them with a strong financial runway into 2028 and ongoing partnership discussions could further bring in non-dilutive funding. Overall, Ocugen's strong pipeline, compelling clinical data, and upcoming catalysts make it uniquely positioned for success in the competitive biopharmaceutical industry.

Bears say

Ocugen is a clinical-stage biotech company with a pipeline focused on gene and cell therapies and vaccines. While they have promising treatments in development, there are several risks, including potential regulatory requirements and clinical trial results. Additionally, Ocugen is a development-stage company without any revenue and may need to raise additional funds in the future, which could be dilutive for shareholders. These factors, combined with the uncertainty of success for their pipeline products, lead to a negative outlook on Ocugen's stock.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.